Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons — 29 U.S. Jurisdictions, May 22–September 3, 2022

Possible Undetected Mpox Infection Among Persons Accessing Homeless Services and Staying in Encampments — San Francisco, California, October–November 2022

“…SFDPH and community partners collaborated to conduct pop-up vaccination events in San Francisco during September-December 2022 for persons experiencing homelessness; this active outreach approach can be further leveraged to better facilitate complete vaccination for eligible persons. A single mpox vaccine dose might still offer some protection against severe mpox-associated illness and hospitalization, for which persons experiencing homelessness (1,7,8) might be at higher risk.…”

Complement-dependent mpox virus-neutralizing antibodies in infected and vaccinated individuals

“…Mpox incidence was 7.4-and 9.6-times lower in individuals having received on one or two doses of JYNEOS, respectively 65 , suggesting an impact of vaccination on mpox outbreak decline. The clinical forms of mpox were also milder in recently vaccinated than in unvaccinated patients 66 . Associating NAbs levels to clinical vaccine efficacy will help defining correlates of protection against MPXV infection or disease severity.…”

Anti‐Monkeypox Infection Approaches: From Prevention to Therapeutic Lines

“…Further studies are needed to clarify the durability of MVA‐BN protection; however, evidence supports its protection against Mpox, and all eligible people are recommended to complete the two‐dose vaccination series 28,35 . In addition, comparing demographic and clinical characteristics of patients with Mpox who received one dose of MVA‐BN vaccine 14 days or more before illness onset with unvaccinated patients with Mpox revealed that symptoms including fever, headache, malaise, and chills were significantly lower among vaccinated patients than unvaccinated patients 38 . To achieve the most effective protection against Mpox, all eligible individuals should receive the two‐dose vaccination series.…”

“…To achieve the most effective protection against Mpox, all eligible individuals should receive the two‐dose vaccination series. One dose of the MVA‐BN vaccine may reduce the severity of the disease and hospitalization in patients who become infected after vaccination 38 . Although MVA‐BN vaccine is contraindicated for people who have atopic dermatitis or have had a severe allergic reaction to a previous dose, there are no contraindications to using it in an emergency situation 28,30 …”